Emerging Growth Patterns Driving Rapid Expansion in the Incretin-Based Drugs Market

The incretin-based drugs market is positioned for significant expansion in the coming years, driven by multiple health and innovation factors. As concerns around obesity and metabolic health intensify globally, the market is set to respond with evolving therapies and treatment options. Let's explore the projected market size, key players, emerging trends, and detailed segment insights that define this promising pharmaceutical sector.

Forecasted Market Size and Growth of the Incretin-Based Drugs Market
The global incretin-based drugs market is expected to reach a value of $39.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1%. This upward trajectory is largely fueled by the escalating obesity crisis worldwide, increasing demand for weight management medications, advancements in long-acting incretin formulations, personalized approaches to diabetes care, and a growing emphasis on preventive metabolic health. Notable trends anticipated during this period include the swift uptake of GLP-1 receptor agonists, broader indications for obesity management, rising use of oral incretin therapies, the growing popularity of combination treatment methods, and enhanced patient adherence thanks to convenient weekly dosing schedules.

Download a free sample of the incretin-based drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Prominent Players Steering the Incretin-Based Drugs Market Forward
A number of leading pharmaceutical companies dominate the incretin-based drugs market, including Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, and Mitsubishi Tanabe Pharma Corporation.

Strategic Moves Highlighted by Roche's Acquisition of Carmot Therapeutics
In July 2024, Roche, the Swiss pharmaceutical giant, completed a $2.7 billion acquisition of Carmot Therapeutics, a US-based clinical-stage biotech firm specializing in obesity and diabetes treatments. This acquisition aims to bolster Roche's foothold in the fast-expanding market for obesity and metabolic diseases by incorporating Carmot's cutting-edge injectable and oral therapies, particularly those targeting incretin pathways such as GLP-1 and GIP receptor agonists, into Roche's pharmaceuticals portfolio.

View the full incretin-based drugs market report:
https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Emerging Market Trends Shaping the Future of Incretin-Based Drugs
Pharmaceutical companies are increasingly focusing on developing generic versions of incretin-based drugs to deliver more affordable and accessible treatment options for type 2 diabetes patients. A generic drug contains the same active ingredients, dosage, and administration route as its brand-name counterpart but is marketed without brand labeling, often reducing costs. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based firm, launched the first FDA-approved generic version of Victoza (liraglutide) injection in the United States. This product is designed as an adjunct to diet and exercise to improve blood sugar control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a budget-friendly alternative amid shortages of GLP-1 medications.

Detailed Breakdown of Incretin-Based Drugs Market Segments
The report categorizes the incretin-based drugs market into key segments:

1) By Type:
- Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route of Administration:
- Oral
- Injectable

3) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

4) By Application:
- Type 2 Diabetes
- Obesity
- Other Applications

Further subcategories include:
- GLP-1 Agonists such as Exenatide, Liraglutide, Dulaglutide, Semaglutide, and Lixisenatide
- DPP-4 Inhibitors including Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, and Vildagliptin

This comprehensive segmentation helps clarify the landscape of incretin-based therapies and highlights the diversity of treatment options available to patients and healthcare providers.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.